Added to YB: 2026-04-16
Pitch date: 2026-04-13
ZVRA [bullish]
Zevra Therapeutics, Inc.
+6.67%
current return
Author Info
EAA Partners shares insights and investment theses on global companies, driven by in-depth research and long-term conviction. Sign up for the newsletter.
Company Info
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
Market Cap
$570.7M
Pitch Price
$9.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
648.42
P/E
7.20
EV/Sales
4.16
Sector
Pharmaceuticals
Category
value
Zevra Therapeutics, Inc. - $ZVRA
ZVRA: FDA approved MIPLYFFA (arimoclomol) for NPC Sept 2024; 1st full yr rev $87.4M. Q4'25: 24 new enrolment forms (strongest qtr). 161 cumulative pts @ ~$875K-$1.1M net/pt annually. EMA MAA under review; EU approval H1'27 could add $50-$100M/yr by FY28. SDX portfolio sold for $50M; repaid $63M debt. Pro-forma $226M net cash, zero debt.
Read full article (37 min)